Therapeutic targeting of VEGFR2 in HBV-associated hepatocellular carcinoma
- PMID: 33971142
- DOI: 10.1016/S2468-1253(21)00134-5
Therapeutic targeting of VEGFR2 in HBV-associated hepatocellular carcinoma
Conflict of interest statement
DJP received lecture fees from ViiV Healthcare, Eisai, Bristol Myers Squibb (BMS), Roche, and Bayer Healthcare; travel expenses from BMS, Merck Sharp & Dohme (MSD), and Bayer Healthcare; consulting fees from Mina Therapeutics, Eisai, Roche, AstraZeneca, and Da Volterra; and received research funding (to institution) from MSD, BMS, and Biognosys. NV received honoraria from Merck Serono, Pfizer, Bayer, Eli Lilly, and Menarini Silicon Biosystems. AC received consulting fees from MSD, BMS, AstraZeneca, and Roche; and speaker's fees from AstraZeneca, MSD, Novartis, and Astellas. AM declares no competing interests.
Comment on
-
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.Lancet Gastroenterol Hepatol. 2021 Jul;6(7):559-568. doi: 10.1016/S2468-1253(21)00109-6. Epub 2021 May 8. Lancet Gastroenterol Hepatol. 2021. PMID: 33971141 Clinical Trial.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical